<DOC>
	<DOCNO>NCT01639885</DOCNO>
	<brief_summary>This study investigate feasibility immunogenicity triple combination gemcitabine , Peg-Intron p53 SLP vaccination patient platinum-resistant ovarian cancer .</brief_summary>
	<brief_title>Chemo-immunotherapy ( Gemcitabine , Interferon-alpha 2b p53 SLP ) Patients With Platinum-resistant Ovarian Cancer</brief_title>
	<detailed_description>Recurrent ovarian cancer dismal prognosis press need identify efficient therapy . Ovarian cancer highly immunogenic good survival tightly link presence tumor-infiltrating T cell absence immunosuppressive immune cell . This anti-tumor immune response might prim chemotherapy . Gemcitabine immune-modulatory property addition direct cytotoxic effect platinum resistant ovarian cancer . Additionally , Peg-Intron allow full maturation dendritic cell , thereby enhance anti-tumor response . Moreover , tumor-associated self-antigen p53 commonly over-expressed ovarian cancer serve target immunotherapy . Therefore , chemo-immunotherapy gemcitabine Peg-Intron plus/minus p53 SLP vaccination seem attractive treatment recurrent , p53+ ovarian cancer patient .</detailed_description>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<mesh_term>Peginterferon alfa-2b</mesh_term>
	<criteria>Histological proven epithelial ovarian cancer , peritoneal cavity fallopian tube cancer ( inclusive mucinous clear cell tumor ) Tumor overexpressing p53 Progression disease relapse previous therapy platinum Measurable disease ( RECIST 1.1 ) elevate CA125 &gt; 2 time upper limit normal within 3 month confirm Age ≥ 18 year WHO performance status 02 Adequate bone marrow function : WBC ≥ 3.0 x 109/l , neutrophil ≥ 1.5 x 109/l , platelet ≥ 100 x 109/l Adequate liver function : bilirubin ≤ 1.5 x upper limit normal ( UNL ) range , ALAT and/or ASAT ≤ 2.5 x UNL , Alkaline Phosphatase ≤5 x UNL Adequate renal function : calculated creatinine clearance ≥ 50 mL/min Survival expectation &gt; 3 month Patients must accessible treatment followup Written inform consent accord local Ethics Committee requirement Previous malignancy within 5 year , exception history previous basal cell carcinoma skin preinvasive carcinoma cervix . Serious disease recent myocardial infarction , clinical sign cardiac failure clinically significant arrhythmia Known hypersensitivity reaction component treatment Pregnancy lactate Medical psychological condition opinion investigator would permit patient complete study sign meaningful inform consent</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>p53 overexpression</keyword>
	<keyword>platinum-resistant</keyword>
</DOC>